BCR-ABL tyrosine-kinase antagonists, like imatinib, popularly used as the drug of choice in patients with chronic myeloid leukemia (CML), inhibits ATP binding to the BCR-ABL kinase receptor, hence leading to apoptosis in tumor cells. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.